-+ 0.00%
-+ 0.00%
-+ 0.00%

Independent Director Michael Miller Sold A Bunch Of Shares In Puma Biotechnology

Simply Wall St·11/15/2026 12:36:13
Listen to the news

We'd be surprised if Puma Biotechnology, Inc. (NASDAQ:PBYI) shareholders haven't noticed that the Independent Director, Michael Miller, recently sold US$121k worth of stock at US$8.10 per share. The eyebrow raising move amounted to a reduction of 28% in their holding.

Puma Biotechnology Insider Transactions Over The Last Year

Notably, that recent sale by Michael Miller is the biggest insider sale of Puma Biotechnology shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$7.77. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

In the last year Puma Biotechnology insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

View our latest analysis for Puma Biotechnology

insider-trading-volume
NasdaqGS:PBYI Insider Trading Volume November 15th 2026

I will like Puma Biotechnology better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Insider Ownership Of Puma Biotechnology

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 14% of Puma Biotechnology shares, worth about US$56m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Puma Biotechnology Insiders?

Insiders sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. While insiders do own shares, they don't own a heap, and they have been selling. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Puma Biotechnology. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of Puma Biotechnology.

But note: Puma Biotechnology may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.